Related Experiment Video
Updated: Apr 6, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Managing anticoagulation in patients receiving implantable cardiac devices
Neil Mangrolia1, Vikrant Nayar, Peter J Pugh
1Box 263, Ward K2, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0QQ, UK.
Insights
Patients with cardiac rhythm devices often need anticoagulation and antiplatelet therapy, creating a balance between bleeding and clotting risks. This review informs best practices for managing these therapies to prevent adverse events.
Area of Science:
- Cardiology
- Thrombosis Management
Background:
- Cardiac rhythm device implantation is common.
- Many patients require anticoagulation to prevent thromboembolism.
- Coexisting cardiovascular diseases often necessitate antiplatelet therapy.
Purpose of the Study:
- To review evidence on managing anticoagulation and antiplatelet therapy in cardiac device patients.
- To inform best practices for balancing hemorrhagic and thromboembolic risks.
Main Methods:
- Literature review of available evidence.
- Synthesis of data on anticoagulation and antiplatelet use.
- Analysis of risks and benefits.
Main Results:
- Patients with cardiac devices face complex therapeutic decisions.
- Balancing anticoagulation and antiplatelet therapy is crucial.
- Evidence guides management strategies.
Conclusions:
- Optimal management requires careful consideration of individual patient risk.
- Evidence-based strategies can mitigate complications.
- Informed decision-making is key for patient safety.
Abstract:
A substantial proportion of patients who undergo cardiac rhythm device implantation receive anticoagulation to prevent thromboembolism. Many patients have coexisting cardiovascular diseases treated with antiplatelet therapy. Anticoagulation may increase the risk of hemorrhagic complication, while withdrawal of anticoagulation may increase thromboembolic risk. In this article, we review and describe the available evidence, in order to inform best practice .
More Related Videos
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Cardiac Catheterization IV: Nursing Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Endocarditis IV: Nursing Management
Dysrhythmias VI: Management of Dysrhythmias

